Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Scrip Overview
Around the Clock, Around The World
Commercial Pharma Insight For
Well-Informed Decision-Making.
Request a Free Trial Today
When News Is Not Enough
Scrip is the trusted source for business-critical market and competitor insights in the commercial biopharma sector.

When news is not enough, Scrip delivers the “so what?" behind the headlines taking you deeper into the issues driving our industry forward through original reporting and access to best-in-class data. It covers:
  • Trends
  • Breaking news
  • R&D
  • Product approvals
  • Financing
  • Licensing
  • Partnerships
  • Mergers & acquisitions
  • Financial Markets
  • Much more
Comprehensive Coverage
From Trusted Experts
Featuring coverage from more than 20 analysts, Scrip is produced by the veteran journalists behind legacy Pharma Intelligence publications Scrip Intelligence, PharmAsia News, and Start-Up.
If you have an active subscription to any of these titles,
you now have access to all of the content in all three products through Scrip.
A Unified Portfolio
The new Scrip benefits from a truly global footprint and deeper emphasis on startup technologies to provide a singular, comprehensive insights solution for the commercial pharma community.
Streamlined Access To Content
User-friendly, personalized, and responsive,
Scrip is housed on a new, mobile-optimized site.
Interactive Features
The platform’s interactive features such as video, audio, and proprietary data sets bring our analyses to life, while content pages suggest articles for further reading to save you time.
Robust Search Function
Scrip’s search function retrieves relevant links from across all other Pharma Intelligence Insights publications, and articles can be saved and shared with one click.
Custom Email Alerts
You also don't have to remember to log in to access the information you need. You can set custom email alerts on any topic so you always stay several steps ahead.
The Year In Preview

If you are not yet a Scrip subscriber, please click on the button below to request your free trial.
Request Your Free Trial
A shift in the US drug-pricing scheme?
Signs point to yes.
"With Trump continuing to push on drug pricing, industry is going to have to move beyond its arguments about value and be more transparent."
– Mary Jo Laffler, Executive Editor, US Commercial

Read More > Pharma's Pricing Debate Splinters As US Political Confrontation Looms
Read More > Pharma's Middlemen Get Fatter: PBM, Health Plan Rebates Near $58bn

A big year for M&A?
Most likely.
"2017 will be an exciting year for M&A as big pharma looks to use its cash stockpiles to drive growth. Potential corporate tax reform will be a big element affecting the M&A landscape."
– Jessica Merrill, Senior Editor, US Commercial

Read More > Big Pharma Is Back In The M&A Driver's Seat For 2017
Read More > Pharma Is Ready And Waiting For A Tax Holiday Under Trump

A shake up on the diabetes landscape?
You may rely on it.
"I'm expecting the launch of a basal insulin biosimilar to shake things up in 2017. Will big pharma come up with new pricing models for branded products or hope that newer drugs will win over customers?"
– Sukaina Virji, Managing Editor, Europe, Commercial

Read More > Novo Nordisk 'Caught Short' By Lantus Exclusion
Read More > Sanofi's Franchise Defense Sees Biosimilar Insulin Lispro Under EU Review

Free Article Pack
Biopharma's Top Themes of 2016
If you are not yet a Scrip subscriber, please click on the button below to start your free trial.
Start Your Free Trial
Top company stories by reader hits:
Top U.S. election stories by reader hits:
Top Brexit stories by reader hits:
The Pharma year in review:
Scrip Has Your Big Questions Covered
  • Are there gaps in my competitor’s pipeline that we should be exploiting?
  • How did that drug get fast track approval and how can apply those insights to my R&D?
  • What are payers looking for in reimbursements?
  • What markets are prime for expansion?
  • What are the implications of that merger on my organization?
If you find you need further answers, your Scrip subscription gives you
access to our pool of analysts who can dig deeper to deliver the insight you need.
Insight Beyond The Sound Bite
2016's Top Interview Exclusives
John Lechleiter,
CEO of Eli Lilly

Outgoing Eli Lilly CEO and president Lechleiter looks back over his biggest strategic decisions while at the helm of the pharma major.
Read Interview
Kasim Kutay,
CEO of Novo A/S

The holding and investment group chief talks to Scrip about the challenges for commercialization strategies on the back of the recent wave of R&D productivity.
Read Interview
Dan Chen,
Roche Global Head of Cancer Immunotherapy Development

With nine immuno-oncology assets in the clinic & its PD-L1 inhibitor Tecentriq clearing FDA, the time is now for Roche to make its mark in cancer immunotherapy, Chen explains.
Read Interview
Ask The Analyst™
Learn About Scrip's Analyst Support Service For Your Commercial Biopharma Questions.
Consultancy Value With Every Scrip Subscription.
Ask The Analyst™ is the bespoke analyst support service of Pharma Intelligence included in all Scrip subscriptions.

With it, subscribers submit specific questions about news stories, market trends, or business issues to our analyst team and receive data-driven, actionable insight within days.

It's consultancy value rolled into a convenient news and analysis solution.
Ask The Analyst
Scrip Ask The Analyst™
View the Full Infographic
In the fast moving pharmaceutical market, Scrip is the competitive advantage you can’t afford to be without.

Spend less time deciphering the critical trends, innovations, licensing developments, mergers, and partnerships affecting global biopharma, and more time applying Scrip insights to your forward-looking strategies.

Book a free trial of Scrip today.
Request a Free Trial Today
Scrip Pipeline Watch.
A Tool For The Inside Track On Clinical Trials.
Have you used Pipeline Watch to track your competitors' clinical trial milestones?
Collated and published by Scrip's editorial team, Pipeline Watch delivers summary details of the most important clinical trial advances of the previous week including Phase II and Phase III trial initiations, development discontinuations, and the release of top-line and full clinical trial results.
Go To Pipeline Watch
Scrip Pipeline Watch
View the Full Infographic
Free Article Pack From Scrip:
The Path to the Largest Generics Deal in History
Foretelling The News.
Extracting the Insights.
When Teva Pharmaceuticals announced plans to acquire a major player in the generics space, we helped subscribers stay ahead of the headlines and understand the implications of the firm's $40.5bn deal with Allergan.
  1. Teva CEO Suits Up For Acquisitions As A Springboard For Growth
  2. Teva to buy Allergan Generics; Mylan off the hook but Perrigo still wriggling
  3. Teva Embarks On New Phase With FTC Clearance Of Allergan Generics
  4. Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches
  5. Allergan Sees Growth From New Launches, Not Big M&A
View the Full Infographic